(Q44543678)

4 December 2017

title

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients (English)

1 reference

4 December 2017

1 reference

1 reference

Mark Boyd

2

0 references

Kiat Ruxrungtham

1

object named as

Kiat Ruxrungtham

1 reference

4 December 2017

S Eralp Bellibas

3

1 reference

4 December 2017

Xiaoping Zhang

4

1 reference

4 December 2017

Albert Dorr

5

1 reference

4 December 2017

Stanley Kolis

6

1 reference

4 December 2017

Tosca Kinchelow

7

1 reference

4 December 2017

Neil Buss

8

1 reference

4 December 2017

Indravadan H Patel

9

1 reference

4 December 2017

language of work or name

1 reference

1 July 2004

1 reference

The Journal of Clinical Pharmacology

4 December 2017

published in

1 reference

4 December 2017

volume

44

1 reference

4 December 2017

issue

7

1 reference

4 December 2017

page(s)

793-803

1 reference

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Differential Effect of HIV-1 Protease Inhibitors on P-Glycoprotein Function in Multidrug-Resistant Variants of the Human CD4+ T Lymphoblastoid CEM Cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

The influence of sex on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004266489

21 January 2018

Identifiers

DOI

10.1177/0091270004266489

1 reference

4 December 2017

1 reference